Table 2. Microbiological data according to survival of critically ill cancer patients with pneumonia.
| All Patients n = 325 (100%) | Survivors n = 114 (35%) | Nonsurvivors n = 211 (65%) | P Value | |
|---|---|---|---|---|
| Microbiological confirmation | 169 (52%) | 53 (47%) | 116 (55%) | 0.163 |
| Adequate antibiotic therapy 1 | 136 (81%) | 45 (85%) | 91 (78%) | 0.405 |
| Positive blood culture | 40 (24%) | 15 (28%) | 25 (22%) | 0.338 |
| Gram-negative bactéria | 99 (59%) | 36 (68%) | 63 (54%) | 0.130 |
| Pseudomonas aeruginosa | 41 (24%) | 10 (19%) | 31 (27%) | 0.335 |
| Klebsiella pneumoniae | 15 (9%) | 4 (8%) | 11 (10%) | 0.779 |
| Gram-positive bactéria | 69 (41%) | 22 (42%) | 47 (41%) | 0.999 |
| Staphylococcus aureus | 42 (25%) | 12 (23%) | 30 (26%) | 0.705 |
| Streptococcus pneumoniae | 21 (12%) | 10 (19%) | 11 (10%) | 0.129 |
| MR Pathogens 2 | 23 (14%) | 6 (11%) | 17 (15%) | 0.636 |
| MRSA | 11 (7%) | 3 (6%) | 8 (7%) | 0.999 |
| ATS Guideline adherence 3 | 53 (16%) | 25 (22%) | 28 (13%) | 0.058 |
| Macrolide use | 66 (20%) | 30 (26%) | 36 (17%) | 0.060 |
| Atypical pathogen coverage | 116 (36%) | 52 (46%) | 64 (30%) | 0.007 |
| Only quinolone use | 50 (15%) | 22 (19%) | 28 (13%) | 0.197 |
| Number of antimicrobial agentes | ||||
| 1 | 154 (47%) | 45 (40%) | 109 (52%) | 0.037 |
| 2 | 126 (39%) | 49 (43%) | 77 (37%) | |
| > 2 | 44 (14%) | 17 (15%) | 27 (13%) |